【摘要】 目的研究异环磷酰胺(IFO)联合长春瑞滨(NVB)的非铂类方案治疗非小细胞肺癌的疗效、毒性以找到一种临床上更有效方案。方法107例晚期非小细胞肺癌患者,采用IFO 1．5g/m~2静脉滴d1～d4,NVB 25mg/m~2静脉滴d1、d8,每3周重复,至少用2个周期。结果完全缓解3例．部分缓解48例,有效率47．7%；中位生存期10．3个月,1年生存率42%,2年生存率12．3%；主要的毒副反应为血液毒性,白细胞下降83．2%,其中Ⅲ～Ⅳ度37．4%；恶心呕吐24．3%。结论该方案是治疗晚期非小细胞肺癌较好的方案,毒副反应能耐受,是理想的值得临床首选的非铂类方案。更多还原

【Abstract】 Objective To evaluate therapeutic effects and toxicity of advanced non-small cell lung cancer (NSCLC)treated by combining chemotherapy on ifosfamide(IFO)and vinorelbine(NVB).Methods 107 cases pa- tients with advanced NSCLC were enrolled.IFO was given in a dosage of 1.5g/m~2 on day 1 to 4.and NVB in a dosage of 25mg/m~2 on day 1 and 8.It was repeated every three or four weeks,up to two to four cycles.Results Two patients had complete response and 40 patients had partial response.The overall response rate was 47.7% ,the median survival time 10.3 months,1-year and 2-year survival rate was 42% and 12.3%,respectively.The main toxicity was bone marrow suppression.Conclusion The regimen is effective,sale and tolerable in advanced non- small cell lung cancer therapy.更多还原